Hearing Loss and PD Risk Mitigated by Early Hearing Aid Use

TOPLINE: 
Hearing loss is associated with a 26% higher risk for Parkinson’s disease (PD), although hearing aids helped mitigate the risk, a new study shows.
METHODOLOGY:
Researchers analyzed electronic health record data on about 3.6 million veterans (96% male) from the US Department of Veterans Affairs.
Hearing loss was confirmed through audiograms conducted between 1999 and 2022.
Participants were categorized on the basis of hearing loss severity: mild (20 to < 35 dB), moderate (35 to < 50 dB), moderate to severe (50 to < 65 dB), and severe to profound (65-120 dB).
The primary outcome was the incidence of PD, and the mean follow-up period was 7.6 years.
TAKEAWAY:
Hearing loss was associated with a 26% higher risk for PD at 10 years (hazard ratio, 1.26; P < .001) compared with having normal hearing.
The cumulative incidence of PD was higher in veterans with hearing loss in a dose-dependent manner, with the greatest increase observed in the first 10 years of follow-up.
Receipt of a hearing aid was associated with a significant decrease in incident PD as early as 1 year after the audiogram in those who received a hearing aid, both among all individuals and the subgroup with impaired hearing.
The presence of hearing loss and prodromal PD resulted in a higher risk for PD than either condition alone.
IN PRACTICE:
“Given that hearing loss, even that of mild severity, synergizes with known prodromal disorders and leads to a greater than additive risk of incident PD, hearing screening should be enforced at the primary care level even in the absence of a patient expressing hearing concerns. Hearing screening and hearing intervention are low-cost, low-risk interventions that may influence later development of synucleinopathy,” the authors wrote.
SOURCE:
The study was led by Lee E. Neilson, MD, Oregon Health & Science University, Portland, Oregon. It was published online on October 21 in JAMA Neurology.
LIMITATIONS: 
The study focused on US veterans, mostly White men, thereby limiting its generalizability. The study did not examine potential confounding factors such as ototoxic drug exposure
DISCLOSURES:
This study was supported by Veterans Affairs Biomedical Laboratory Research and Development, John and Tami Marick Family Foundation, Collins Medical Trust Award, Oregon Health & Science University Medical Research Foundation, Veterans Affairs Clinical Science Research and Development, and National Center for Rehabilitative Auditory Research. One author disclosed being a co-inventor on a patent for an ototoxicity monitoring method.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
 
Send comments and news tips to [email protected].